View ValuationNextleaf Solutions 将来の成長Future 基準チェック /06現在、 Nextleaf Solutionsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長39.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Mar 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (CA$10.2m market cap, or US$7.45m). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change).Reported Earnings • Mar 05First quarter 2026 earnings released: EPS: CA$0.002 (vs CA$0.003 in 1Q 2025)First quarter 2026 results: EPS: CA$0.002 (down from CA$0.003 in 1Q 2025). Revenue: CA$3.02m (up 4.6% from 1Q 2025). Net income: CA$259.2k (down 51% from 1Q 2025). Profit margin: 8.6% (down from 18% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 03Nextleaf Solutions Ltd., Annual General Meeting, Apr 30, 2026Nextleaf Solutions Ltd., Annual General Meeting, Apr 30, 2026.Reported Earnings • Jan 29Full year 2025 earnings released: CA$0.001 loss per share (vs CA$0.009 loss in FY 2024)Full year 2025 results: CA$0.001 loss per share (improved from CA$0.009 loss in FY 2024). Revenue: CA$11.3m (down 9.7% from FY 2024). Net loss: CA$162.9k (loss narrowed 89% from FY 2024). Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 31Third quarter 2025 earnings released: EPS: CA$0 (vs CA$0.002 loss in 3Q 2024)Third quarter 2025 results: EPS: CA$0 (improved from CA$0.002 loss in 3Q 2024). Revenue: CA$2.91m (down 4.5% from 3Q 2024). Net loss: CA$11.9k (loss narrowed 96% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Reported Earnings • Jun 02Second quarter 2025 earnings released: EPS: CA$0.002 (vs CA$0.006 loss in 2Q 2024)Second quarter 2025 results: EPS: CA$0.002 (up from CA$0.006 loss in 2Q 2024). Revenue: CA$3.52m (up 2.9% from 2Q 2024). Net income: CA$348.8k (up CA$1.36m from 2Q 2024). Profit margin: 9.9% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.New Risk • May 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$229k free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Market cap is less than US$10m (CA$9.17m market cap, or US$6.59m).Reported Earnings • Mar 04First quarter 2025 earnings released: EPS: CA$0.003 (vs CA$0.001 in 1Q 2024)First quarter 2025 results: EPS: CA$0.003 (up from CA$0.001 in 1Q 2024). Revenue: CA$2.89m (down 9.9% from 1Q 2024). Net income: CA$530.4k (up 299% from 1Q 2024). Profit margin: 18% (up from 4.1% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.お知らせ • Jan 31Nextleaf Solutions Ltd. Auditor Raises 'Going Concern' DoubtNextleaf Solutions Ltd. filed its Annual on Jan 29, 2025 for the period ending Sep 30, 2024. In this report its auditor, Davidson & Company, gave an unqualified opinion expressing doubt that the company can continue as a going concern.Reported Earnings • Jan 29Full year 2024 earnings released: CA$0.009 loss per share (vs CA$0.001 profit in FY 2023)Full year 2024 results: CA$0.009 loss per share (down from CA$0.001 profit in FY 2023). Revenue: CA$12.5m (up 53% from FY 2023). Net loss: CA$1.44m (down CA$1.66m from profit in FY 2023). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.お知らせ • Dec 26Nextleaf Solutions Ltd. Announces 14 New Product Listings Nationwide Across 4 CategoriesNextleaf Solutions Ltd. announced 14 new product listings nationally across 4 categories, and the date for their Annual General Meeting, which will be held on January 30th 2025, in Vancouver, BC. New Products and Innovation. Nextleaf announced 14 new listings under their brand Glacial Gold, across 4 categories including vapes, softgels, oils, and infused prerolls. These listings will launch between January and April 2025 nationwide. The product pipeline focuses on smokeless ingestible extracts such as softgels and oils, ready-to-consume convenience formats like All-in-One liquid diamond vapes, infused prerolls, and minor cannabinoid formulations (notably CBG and CBN) across multiple categories. These products solidify Nextleaf's market leadership in these emerging segments. Regional Product Listings. Ontario (4 new listings): Glacial Gold RSO Full Spectrum 5:5 Softgels 100-pack. Glacial Gold Atmosphere Tart Cherry CBN:THC Vape Cartridge 1.2g. Glacial Gold Atmosphere CBN:THC 15mg:15mg Oil Drops 35ml. Alberta (4 new listings: Glacial Gold Liquid Diamonds Pure Diamonds All-in-One Vape 0.95g. Glacial Gold HIGH THC Banger Cherry Bomb All-in-One Vapes 1g. Glacial Gold Atmosp Here CBN:THC 15 mg:15mg Oil Drops 35g. Glacial Gold Atmospwhere CBN:THC 15g:15mg Oil Drops 35 ml. British Columbia (6 new listings): Glacial Gold Atmosphere CBG:THC Tart Cherry Vape Cartridge 1. 2g. Glacial Gold atmospherehere CBN:THC Melon Baller Vape Cartridge1.2g. glacial Gold Atmosphere CBN;THC Oil Drops 35ml. Glacial Gold Liquid Diamonds All-in- One Vape 0.95g; Glacial Gold HIGH THC Bangers Cherry Bomb Infused Preroll 3 x 0.5g (unflavoured) Glacial Gold High THC Banger Cherry Bomb Infused Preroll3 x 0.5g.お知らせ • Dec 02Nextleaf Solutions Ltd., Annual General Meeting, Jan 30, 2025Nextleaf Solutions Ltd., Annual General Meeting, Jan 30, 2025.お知らせ • Sep 26Nextleaf Solutions Ltd. Appoints Emma Andrews as Permanent Chief Executive OfficerNextleaf Solutions Ltd. announced the permanent appointment of Emma Andrews as the Chief Executive Officer of the Company. Andrews has acted as the Company's Interim CEO since September 8, 2023, and has been with the company for 6 years, previously as the Director of Marketing. Emma Andrews helped guide the company's commercial strategy and led the entry into consumer-packaged goods, including the company's re-launch of prohibition-era brand Glacial Gold into the regulated landscape. Andrews brings a wealth of expertise in consumer-packaged goods, having spent over 10 years leading teams, launching brands, and developing products for the natural health industry. She is a Registered Nutritionist (RHN) and certified in New Product Development (NPDP). Her most notable tenure was with plant-based nutrition company Vega, leading to a CAD 750 million acquisition by White Wave Foods in 2015.New Risk • Sep 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (CA$12.4m market cap, or US$9.11m). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (3.3% increase in shares outstanding).Reported Earnings • Sep 01Third quarter 2024 earnings released: CA$0.002 loss per share (vs CA$0.003 profit in 3Q 2023)Third quarter 2024 results: CA$0.002 loss per share (down from CA$0.003 profit in 3Q 2023). Revenue: CA$3.05m (up 37% from 3Q 2023). Net loss: CA$317.3k (down 176% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.New Risk • Jun 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.7m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Reported Earnings • May 30Second quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0 in 2Q 2023)Second quarter 2024 results: CA$0.006 loss per share (further deteriorated from CA$0 in 2Q 2023). Revenue: CA$3.42m (up 57% from 2Q 2023). Net loss: CA$1.01m (loss widened CA$986.7k from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 03First quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.004 loss in 1Q 2023)First quarter 2024 results: EPS: CA$0.001 (up from CA$0.004 loss in 1Q 2023). Revenue: CA$3.20m (up 170% from 1Q 2023). Net income: CA$132.8k (up CA$691.8k from 1Q 2023). Profit margin: 4.1% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 01Full year 2023 earnings released: EPS: CA$0.001 (vs CA$0.025 loss in FY 2022)Full year 2023 results: EPS: CA$0.001 (up from CA$0.025 loss in FY 2022). Revenue: CA$8.18m (up 86% from FY 2022). Net income: CA$223.3k (up CA$3.71m from FY 2022). Profit margin: 2.7% (up from net loss in FY 2022). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.お知らせ • Oct 21Nextleaf Solutions Ltd., Annual General Meeting, Dec 19, 2023Nextleaf Solutions Ltd., Annual General Meeting, Dec 19, 2023.お知らせ • Sep 12+ 1 more updateNextleaf Solutions Ltd. Announces an Executive ChangeThe board of directors of Nextleaf Solutions Ltd. has announced the departure of Paul Pedersen from his role as Chief Executive Officer, effective September 08, 2023. Pedersen had been Nextleaf's CEO since inception and remains on the Board of Directors. The company announced the appointment of Emma Andrews, BA, RHN, NPDP to the role of Interim Chief Executive Officer. Andrews has worked closely with Nextleaf leadership and executive team since the company's origin, most recently as the Director of Marketing she oversaw the company's entry into branded consumer products, and was integral in creating the company's mission, vision, values, and corporate identity. Andrews has held senior management and public company executive officer roles across every vertical in the cannabis industry including cultivation/harvesting, processing, retail, ancillary, and consumer products. This is in addition to over a decade working in the Natural Products Industry to help scale emerging brands into category leaders.Reported Earnings • Sep 03Third quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.007 loss in 3Q 2022)Third quarter 2023 results: EPS: CA$0.003 (up from CA$0.007 loss in 3Q 2022). Revenue: CA$2.22m (up 85% from 3Q 2022). Net income: CA$419.9k (up CA$1.47m from 3Q 2022). Profit margin: 19% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.Reported Earnings • Jun 01Second quarter 2023 earnings released: EPS: CA$0 (vs CA$0.004 loss in 2Q 2022)Second quarter 2023 results: EPS: CA$0 (improved from CA$0.004 loss in 2Q 2022). Revenue: CA$2.17m (up 90% from 2Q 2022). Net loss: CA$25.2k (loss narrowed 96% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 03First quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0.007 loss in 1Q 2022)First quarter 2023 results: CA$0.004 loss per share (improved from CA$0.007 loss in 1Q 2022). Revenue: CA$1.19m (up 3.3% from 1Q 2022). Net loss: CA$559.0k (loss narrowed 39% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.Reported Earnings • Jan 31Full year 2022 earnings released: CA$0.025 loss per share (vs CA$0.044 loss in FY 2021)Full year 2022 results: CA$0.025 loss per share (improved from CA$0.044 loss in FY 2021). Revenue: CA$4.41m (up 31% from FY 2021). Net loss: CA$3.49m (loss narrowed 35% from FY 2021). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Sherry Boodram was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Oct 13Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Sherry Boodram was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 16Nextleaf Solutions Ltd. Announces the Launch of New High THC Vape in Ontario and Additional Product Updates in British ColumbiaNextleaf Solutions Ltd. announced the launch of a new high THC vape in Ontario and additional product updates in British Columbia, including the Company's first cannabinol ("CBN") product. Ontario Glacial GoldTM Update - Nextleaf is excited to announce the launch of a new limited drop Glacial GoldTM vape for Ontario. The new Glacial GoldTM High THC Holiday Fruitquake is a one-gram THC vape cartridge with a holiday inspired flavour that is sweet, fruity, and cakey, reminiscent of one favourite holiday fruitcake. British Columbia Glacial GoldTM Update - Nextleaf has completed its initial shipment of its new one-gram Glacial GoldTM CBD 3:1 Vape in theCompany's signature Berry Lemonade flavour. Consumers can now find this new product in retail stores throughout B.C. Additionally, Nextleaf is delighted to announce its expansion into the rare cannabinoids market segment,specifically CBN, with the launch of Glacial GoldTM After Hours CBN:THC Drops. Formulated for night- time use, Glacial GoldTM After Hours CBN:THC Drops is the perfect blend of THC and CBN to help consumers unwind after a long day. Along with Glacial GoldTM After Hours CBN:THC Drops, there are several new Glacial GoldTM SKU listings ("SKUs") that are set to launch between now and the end of fall in British Columbia. The additional SKUs approved are Glacial GoldTM Session THC Lime Ginger Haze, Glacial GoldTM THC 10mg Softgels, and Glacial GoldTM Rise & Shine CBD Drops. Glacial GoldTM Session THC Lime Ginger Haze is a full potency one-gram THC vape cartridge. The lime ginger haze vape is cocktail inspired and consists of a citrus, lime-forward flavour, with a subtle hint of ginger. The Company has received its initial purchase order from the province and expects theproduct to be available in B.C. in early October. Glacial GoldTM THC 10mg Softgels will launch in B.C. in ten and fifty-pack formats powered by Nextleaf's high-purity cannabis distillate in a base of organic coconut MCT oil expertly encapsulated for a premium consumption experience, without premium pricing. Glacial GoldTM Softgels will provide unparalleled value in quality and price per milligram compared to other regulated capsules and edibleproducts. Glacial GoldTM Rise & Shine CBD Drops is Nextleaf's first product utilizing its technology to produce its excise-exempt ingredient, THC-free Broad Spectrum CBD distillate. The new product is a more holistic alternative to CBD isolates, perfect to start the day with no concern of THC consumption.Reported Earnings • Aug 30Third quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.011 loss in 3Q 2021)Third quarter 2022 results: CA$0.007 loss per share (up from CA$0.011 loss in 3Q 2021). Revenue: CA$1.20m (up 83% from 3Q 2021). Net loss: CA$1.05m (loss narrowed 22% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.お知らせ • Aug 25Nextleaf Solutions Ltd. Announces the Launch of Its First THC-Free Broad Spectrum Cbd Distillate ("THC-Free CBD") ProductNextleaf Solutions Ltd. announced the launch of its first THC-free Broad Spectrum CBD distillate ("THC-Free CBD") product. Glacial GoldTM Rise & Shine CBD Drops is a broad-spectrum alternative to CBD isolates, perfect to start the day without the risk of intoxication. Nextleaf expects Glacial GoldTM Rise & Shine CBD Drops to be available first in adult-use channels in British Columbia and nationally through medical cannabis distribution partners in the fall. On July 28, 2022, Health Canada released a report by its science advisory committee on health products containing cannabis. In the report, the committee unanimously agreed that CBD is safe and tolerable for short-term use at doses from 20 milligrams per day to a max dose of 200 milligrams per day. The report will serve as a tool to inform Health Canada's decision-making in developing a potential pathway for over the counter, non-prescription health products containing CBD for humans and dogs. Nextleaf announced that it has executed its first bulk-sale of THC-Free CBD ingredients to a multinational partner. The Company recently produced THC-Free CBD in anticipation of commercialization and has validated its hemp extraction and manufacturing process through third-party analytical testing. Nextleaf believes that excise-exempt ingredients like THC-Free CBD will be disruptive ingredients within the Canadian market, and in the example of THC-Free CBD, it's an alternative to CBD isolate for those that prefer a more holistic cannabis product.お知らせ • Jul 26Nextleaf Solutions Ltd. Announces Validation of TechnologyNextleaf Solutions Ltd. announced validation of its technology to produce THC-free Broad Spectrum CBD distillate from industrial hemp feedstock. Nextleaf is commercializing its patented technology by utilizing its new distillate-based ingredient to power the next generation of innovative CBD products distributed under the Company's prohibition-era brand, Glacial GoldTM, and supplying bulk THC-Free CBD ingredients to leading global CPG manufacturers in Canada and where cannabinoids are legal. The Company recently produced THC-Free CBD in anticipation of commercialization and has validated its hemp extraction and manufacturing process through third-party analytical testing. Nextleaf expects to announce more details in the coming weeks on the launch of its first THC-Free CBD product, and the sale of bulk cannabinoids to B2B customers that require CBD compliant for distribution in Canada and intentionally.お知らせ • Jul 13Nextleaf Solutions Ltd. Launches Glacial Gold CBD 3:1 VapeNextleaf Solutions Ltd. announced the launch of its new CBD 3:1 vape under the award-winning prohibition-era brand, Glacial GoldTM. The Company's technology stack enables the transformation of industrial hemp biomass into CBD distillate purified to be free of wax, chlorophyll, and residual pesticides. Glacial GoldTM CBD 3:1 Vape is launching as a 1-gram format in the Company's signature Berry Lemonade flavour, reminiscent of fresh-picked berries from the Fraser Valley. The new CBD 3:1 Vape will build off the success of the Glacial GoldTM Session THC Vape and Anytime 1:1 Vape by offering an additional tier of potency at the accessible price point and quality the legacy brand is known for. The Company expects the Glacial GoldTM CBD 3:1 Vape to be available first in the British Columbia market this summer, and nationally through medical cannabis distribution partners. The British ColumbiaLiquor Distribution Branch ("BCLDB") is responsible for the wholesale distribution of cannabis to private retailers in British Columbia and is the public retailer of cannabis throughout the province under the brand 'BC Cannabis Stores'. Glacial GoldTM CBD products are manufactured using Canadian hemp flower processed at Nextleaf Labs in Greater Vancouver, B.C. Additionally, all Glacial GoldTM products are developed through the Company's extensive sensory evaluation program as covered in Forbes.お知らせ • Jun 09Nextleaf Solutions Ltd., Annual General Meeting, Aug 03, 2022Nextleaf Solutions Ltd., Annual General Meeting, Aug 03, 2022.Reported Earnings • Jun 01Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: CA$0.004 loss per share (up from CA$0.01 loss in 2Q 2021). Revenue: CA$1.15m (up CA$1.01m from 2Q 2021). Net loss: CA$606.9k (loss narrowed 49% from 2Q 2021). Revenue missed analyst estimates by 100%. Earnings per share (EPS) also missed analyst estimates by 43%. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings.お知らせ • Jun 01Nextleaf Solutions Ltd. Announces Management ChangesNextleaf Solutions Ltd. announced the addition of Sam Kassem to its Board of Directors pending the issuance of his Health Canada security clearance. Mr. Kassem brings unique qualifications as a CFA charterholder with over 10 years of operational experience from servicing cannabis and hemp processors around the world. Sam Kassem is Co-Founder and President of Root Sciences Inc., one of North America's larger providers of end-to-end processing equipment solutions. Tim Gillis has resigned from the Board to pursue other interests. The Company would like to Mr. Gillis for his contribution since 2019 and wish him well on his future endeavors.お知らせ • Apr 06Nextleaf Solutions Ltd. Announces United States Patent and Trademark Office Granted the Company its 18Th Issued U.S. PatentNextleaf Solutions Ltd. announced that the United States Patent and Trademark Office has granted the Company its 18th issued U.S. patent. Nextleaf's latest U.S. patent describes a system in which spent cannabis biomass is heated in stages to reclaim residual cannabinoids while simultaneously generating carbon with a desired porosity level. When utilized, this patented process allows Nextleaf to maximize its cannabinoid molecule yield, reduce waste destined for landfills, and create a new business vertical at minimal cost. Nextleaf owns one of the largest collections of U.S. patents among all cannabis companies, as well as a Greater Vancouver-based extraction plant producing low-cost cannabinoid ingredients under its Health Canada licences. Nextleaf's multi-patented automated extraction plant up-cycles aged cannabis flower and biomass, which would otherwise be destroyed, into high-purity cannabinoid ingredients at industrial scale.お知らせ • Jan 12Nextleaf Solutions Ltd. Announces Glacial Gold Distilled CBD 200 Oil Available Nationally to Medical Patients Through MendoNextleaf Solutions Ltd., Glacial Gold announced that Distilled CBD 100 Oil and Distilled CBD 200 Oil are available nationally through its medical cannabis distribution partner, Quebec-based Medicibis ("Mendo").Glacial GoldTM Distilled CBD 200 Oil is a first in Canada, with the high amount of CBD in a single unit (5700 mg), high potency of CBD available in an ingestible format, and best dollar value permilligram for CBD in Canada. The Company's multi-patented ingredient processing technology is the secret behind Glacial GoldTM products. Distilled CBD 200 Oil was developed to meet the needs of the everyday CBD consumer. Glacial GoldTM CBD distilled oils are formulated with organic coconut MCT oil and a standardized doseof CBD. In British Columbia, Nextleaf is a top 10 supplier of vapes and oils. Glacial GoldTM has multiple products inside the top 20 best selling SKUs within the vape and oils categories. CBD is increasingly thought of as a potential therapeutic treatment for opioid use disorder. On January4, 2022, the FDA approved human trials evaluating an investigational drug using CBD to be conducted at UCLA and funded by the U.S. National Institute on Drug Abuse.Medical patients including veterans, have made it clear that they need a reliable supply of consistent quality medical cannabis products for those living with PTSD, chronic pain, and other conditions that disproportionately impact veterans. According to a 2019 Veterans Health and Medical CannabisStudy, 96% of veterans reported they experience a much greater quality of life because of their cannabis consumption. As part of the Company's commitment to improving access to medical cannabis, Nextleaf launched an assortment of accessibly priced Glacial GoldTM CBD and THC products for the medical market through Mendo. Quebec is the third-largest cannabis market in Canada, representing approximately 15% of Canadian cannabis retail sales in the country, and approximately 22% of the Canadian population. Canadian spending on medical cannabis totaled $587 million in 2020. Medical cannabis has become an important component of Canadian healthcare, with $119 million of medical cannabis purchases reimbursed by the Federal Government through Veterans Affairs Canada in 2020.お知らせ • Dec 23Nextleaf Solutions Ltd. has completed a Composite Units Offering in the amount of CAD 3 million.Nextleaf Solutions Ltd. has completed a Composite Units Offering in the amount of CAD 3 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 7,500,000 Price\Range: CAD 0.2 Discount Per Security: CAD 0.016 Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 7,500,000 Price\Range: CAD 0.2 Discount Per Security: CAD 0.004 Transaction Features: Regulation Sお知らせ • Sep 24Saskatchewan Liquor and Gaming Authority Authorizes Nextleaf Solutions Ltd. to Supply Glacial GoldTM CBD and THC Products Directly to the Province's Retail and Wholesale MarketsNextleaf Solutions Ltd. announce the Saskatchewan Liquor and Gaming Authority, the provincial regulator responsible for permitting and monitoring the operation of local cannabis wholesalers and retailers in Saskatchewan, has authorized the Company to supply Glacial GoldTM CBD and THC products directly to the province's retail and wholesale markets. The model in Saskatchewan is unique as it allows for both the sale and distribution of cannabis products by the private sector. Consumers in the province can look forward to the launch of Glacial GoldTM as a price-point and value leader in distillate-focused product categories. Glacial GoldTM distillate is produced through the Company's patented, automated closed-loop, chilled-alcohol extraction plant at Nextleaf Labs, a Health Canada licensed processing facility. Nextleaf'sproprietary technology efficiently transforms cannabis and hemp grown in B.C. and throughout Canada into high-purity cannabis distillate at an industrial scale.分析記事 • Sep 16Nextleaf Solutions (CSE:OILS) Is Carrying A Fair Bit Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Jun 25Nextleaf Solutions Ltd. Announces That the United States Patent and Trademark Office Has Granted the Company A Patent Pertaining to the Extraction and Purification of Thc and CbdNextleaf Solutions Ltd. announce that the United States Patent and Trademark Office has granted the Company a patent pertaining to the extraction and purification of THC and CBD. The Company believes it has developed defendable intellectual property around the most efficient methods for producing THC and CBD distillate at scale within a regulated market. Nextleaf owns 15 U.S. patents and has been issued over 80 patents globally.お知らせ • Jun 16Nextleaf Solutions Ltd. to Release Adult-Use Products with THC-O-AcetateNextleaf Solutions Ltd. announce the launch of a Specialty Molecules Division to focus on the development and commercialization of novel psychoactive compounds. The division is supported by the Company's existing intellectual property ("IP") portfolio, including the manufacturing of CBD-O-acetate and the recently announced U.S. patent for the synthesis of THC-O-acetate. Nextleaf intends to develop therapeutic products from its intellectual property pertaining to the acetylation of cannabinoids. The Company expects to release adult-use products with THC-O-acetate, which to the best of the Company's knowledge has never been sold under a legal framework. The Company believes a THC-derived product produced with its patented acetylation process may hold significant potential as a therapeutic due to anecdotal reports of THC-O-acetate having a more gradual onset, longer-lasting effects, and altered psychoactive effects, as compared to Delta-9-THC. The reported enhanced potency may also have potential for reducing the cost per dose and the amount of active ingredient in a formulation to obtain the same level of effect compared to Delta-9-THC. Nextleaf's U.S. and Canadian issued patents describe a process of acetylating THC by refluxing naturally derived THC distillate in the presence of a single reactant, with THC-O-acetate the product of the reaction.分析記事 • Jun 02Is Nextleaf Solutions (CSE:OILS) Weighed On By Its Debt Load?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Jun 02Second quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.012 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CA$130.5k (up 24% from 2Q 2020). Net loss: CA$1.19m (loss narrowed 12% from 2Q 2020).お知らせ • May 21Nextleaf Solutions Ltd. Receives Patent to A Method for Refining Raw Cannabis Plant Material from United States Patent and Trademark OfficeNextleaf Solutions Ltd. announced that the United States Patent and Trademark Office has granted the Company a patent to a method for refining raw cannabis plant material, adding to Nextleaf's already robust and expanding U.S. patent portfolio. Nextleaf's latest U.S. patent covers a method for separating cannabinoid-rich trichomes from lower potency cannabis biomass, including most approved industrial hemp cultivars, which Nextleaf uses to increase the concentration of CBD in hemp biomass. The Company's patented technology significantly increases extraction efficiency and improves the economics of processing hemp into high-purity CBD extracts.お知らせ • Apr 01Nextleaf Solutions Ltd. announced that it has received CAD 3 million in fundingNextleaf Solutions Ltd. (CNSX:OILS) announced that it has entered into a securities purchase agreement with an institutional investor for a private placement of a senior secured convertible note at a price of CAD 3,000,000 for gross proceeds of CAD 3,000,000 on March 31, 2021. The company will also issue a warrant to purchase up to 6,875,000 common shares. The was issued at an original issue discount of 10% and were of the principal amount of CAD 3,300,000. The note will mature on the date that is 18 months from the date of issuance and bear guaranteed interest at a rate of 5% per annum. The warrant is exercisable into common shares at a price of CAD 0.288 per share for a period of 36 months from the date of issuance. The company issued 250,000 common hares at a deemed price of CAD 0.24 per share as fees related to the transaction. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date.お知らせ • Mar 19Nextleaf Solutions Ltd., Annual General Meeting, May 14, 2021Nextleaf Solutions Ltd., Annual General Meeting, May 14, 2021.お知らせ • Mar 11BevCanna Enterprises Inc. Signs Supply Agreement with Nextleaf Solutions LtdBevCanna Enterprises Inc. has signed a supply agreement with Nextleaf Solutions Ltd. BevCanna will have the ability to utilize Nextleaf's Rapid Emulsion Technology by OILSTM (‘Rapid’) THC and CBD concentrate within select BevCanna in-house and white-label products. Made with Nextleaf's high purity cannabis distillate, Rapid's unique structure and composition allows the final ingredient to be fundamentally tasteless, odorless, and achieve optical transparency through uniform and complete dispersion in water. Ten years of prior R&D has resulted in a patent pending emulsion technology adapted to cannabinoids, to deliver rapid onset of THC, CBD, and other cannabinoids. The recent receipt of BevCanna's Health Canada Standard Processing License has allowed the Company to move forward with commercial validation and go-to-market activities, and the Company is actively working with its partners, including Nextleaf, on these initiatives.お知らせ • Mar 06Nextleaf Solutions Supplies Rapid Emulsion to Cannabis-Infused Beverage Manufacturer BevcannaNextleaf Solutions Ltd. announced the initial order of Nextleaf's Rapid Emulsion Technology by OILSTM ("Rapid") THC and CBD to cannabis-infused beverage manufacturer, BevCanna Enterprises Inc. ("BevCanna"). With this initial order, Nextleaf's Rapid concentrate becomes one of BevCanna's preferred ingredients, available for use in both their brands and their partner brands. Rapid is Nextleaf's patent pending delivery technology.Reported Earnings • Mar 04First quarter 2021 earnings released: CA$0.008 loss per share (vs CA$0.012 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CA$1.26m (up 259% from 1Q 2020). Net loss: CA$911.5k (loss narrowed 31% from 1Q 2020).お知らせ • Feb 18Nextleaf Solutions Ltd. Receives Cannabis Extraction Patent in IsraelNextleaf Solutions Ltd. announced the Israeli Patent Office has granted the Company a patent for its foundational process for producing low-cost cannabis distillate, Nextleaf's fifth issued extraction patent in Israel. The Company believes global patent protection is a key aspect of developing defendable intellectual property ("IP") around the most efficient methods for producing high-purity THC and CBD oils within a regulated environment. With the medical cannabis market in Israel continuing to grow along with the tailwind of legalization, Nextleaf views Israel as a key jurisdiction for cannabinoid IP rights. In December 2020, Israel signed a regulatory amendment permitting the use of CBD in cosmetics and food products. According to the Israeli Medical Cannabis Association, there are over 71,000 legal medical cannabis patients, in addition to an estimated $2 Billion in illicit cannabis consumption in Israel. Nextleaf owns one of the large portfolios of issued U.S. patents related to cannabis extraction, and has been issued patents in Canada, Mexico, Australia, New Zealand, Colombia, South Africa, Cambodia, Israel, Germany, the U.K. and across Europe.お知らせ • Jan 20Nextleaf Solutions Grants Patent for CBD Prodrug and Prepares for Pharmaceutical ParticipationNextleaf Solutions Ltd. announced that the Canadian Intellectual Property Office has granted the company a patent for the acetylation of cannabinoids. More specifically, the patent covers a process for acetylating cannabidiol ("CBD"), and subsequent refinement of CBD-O-Acetate using a proprietary extraction and distillation technique. The company owns 12 issued U.S. patents and 70 issued patents globally for the extraction, purification, and delivery of cannabinoids - representing the patent portfolio among all cannabis companies. This patented process to produce CBD-O-Acetate enables the standardization of a more potent analog of CBD through targeted drug delivery. Prodrugs utilize various physical and chemical modifications to improve features of active drugs. Maintaining the integrity of the molecule and its ability to deliver drugs to precisely targeted areas in the body may increase efficacy for desired outcomes. The company believes an orally consumable CBD metabolic prodrug produced under its patented process for acetylating cannabidiol will enhance the therapeutic potency of CBD. OILS already owns U.S. patents for the acetylation of THC, and the acetylation of CBD. The company's patent portfolio and Health Canada licenses for cannabis processing and research presents an entry point for pharmaceutical firms looking to manufacture cannabinoid prodrugs in a federally legal jurisdiction. The company plans to commercialize this intellectual property ("IP") through IP licensing, and the production of IP protected cannabinoid-based products as legally permitted by Health Canada. Nextleaf has engaged Kronos Capital Partners Inc. ("Kronos") to pursue and evaluate global strategic partners and investors. Kronos is a strategic advisor and an active investor in the global cannabis and life science sectors.お知らせ • Jan 12Nextleaf Solutions Ltd. Wins U.S. Patent for Cannabis Extract and Launches CBD OilsNextleaf Solutions Ltd. announced that the United States Patent and Trademark Office has granted the Company a patent for a process resulting in a solventless cannabis concentrate, adding to the Company's dynamic and expanding U.S. patent portfolio. The Company owns 12 issued U.S. patents and over 60 issued patents globally for the extraction, purification, and delivery of cannabinoids. Nextleaf's latest U.S. patent covers a process whereby trichomes are made brittle from exposure to low temperatures and separated from plant material during agitation and through a series of filtration. The result is a proprietary full melt bubble hash concentrate, a product category that makes up approximately 10% of the cannabis market in the United States. This patent further enriches the Company's intellectual property around differentiated formats and delivery technology. OILS commercializes its intellectual property in Canada through its wholly-owned subsidiary, Nextleaf Labs Ltd. Nextleaf Labs delivered approximately 100 kilos of CBD distillate to one of Canada's top selling cannabis brands during the month of December. Nextleaf Labs' bulk cannabis distillate supply agreement is with a British Columbia-based licensed producer and one of the largest distributors of cannabis products in Canada. Nextleaf expects to continue supplying CBD distillate to the Partner for the purposes of manufacturing CBD based products, with distribution of the Partner's branded consumer products through their existing sales channels.Is New 90 Day High Low • Jan 07New 90-day high: CA$0.21The company is up 16% from its price of CA$0.18 on 09 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 60% over the same period.お知らせ • Nov 27Nextleaf Solutions Granted Mexican Patent and Signs Cannabis Extraction AgreementNextleaf Solutions Ltd. to provide the following commercial and intellectual property update: Cannabis Extraction Agreement with White Label Producer: The Company's wholly owned subsidiary Nextleaf Labs Ltd. has entered into a Cannabis Extraction Agreement with a licensed producer in Ontario, which is a premium white label flower producer. Pursuant to the Extraction Agreement, the Client provides cannabis biomass to be processed into THC distillate by Nextleaf Labs. The extraction services may be paid in-kind, with Nextleaf Labs retaining a portion of the resulting bulk THC distillate. The initial term of the Agreement will end on the earlier of (a) 12 months, and (b) the date upon which 1,000 kilos of marijuana have been processed by Nextleaf Labs. Nextleaf Labs wholesales THC and CBD oils through its Commercial Partners Program and provides cannabis extraction services. The Company's investment in intellectual property and its automated closed-loop extraction plant provides a clear competitive advantage supplying low-cost cannabinoid distillate. The Mexican Institute of Industrial Property has granted OILS a patent for the Company's foundational process for producing high-purity cannabinoid distillate. On September 19, 2020 the Mexican Senate approved a comprehensive adult-use marijuana legalization bill. The pending law requires President Andrés Manuel López Obrador signing the bill into law, which will make Mexico the third country to legalize adult-use cannabis, following Canada and Uruguay. Once signed, Mexico will become the legal cannabis market in the world, based on population. Nextleaf owns the second patent portfolio of any cannabis company, and has been issued patents in Canada, the United States, Israel, Australia, New Zealand, Mexico, Colombia, South Africa, the U.K. and across Europe. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Nextleaf Solutions は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CNSX:OILS - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202511001N/A9/30/202511000N/A6/30/202512100N/A3/31/202512000N/A12/31/202412-100N/A9/30/202412-1-1-1N/A6/30/202412-100N/A3/31/202411001N/A12/31/202310100N/A9/30/20238011N/A6/30/20236-111N/A3/31/20235-300N/A12/31/20224-3-1-1N/A9/30/20224-3-1-1N/A6/30/20225-5-2-2N/A3/31/20224-5-3-3N/A12/31/20213-5-3-2N/A9/30/20213-5-3-3N/A6/30/20212-6-3-3N/A3/31/20212-5-3-3N/A12/31/20202-6-4-3N/A9/30/20201-6-6-3N/A6/30/20200-6-7-4N/A3/31/20200-6-7-4N/A12/31/20190-10-7-5N/A9/30/2019N/A-9N/A-4N/A6/30/20190-8N/A-4N/A3/31/20190-6N/A-3N/A12/31/20180-3N/A-2N/A9/30/20181-2N/A-1N/A6/30/20180-2N/A-1N/A9/30/20170-1N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: OILSの予測収益成長が 貯蓄率 ( 3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: OILSの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: OILSの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: OILSの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: OILSの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: OILSの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/07 00:17終値2026/05/07 00:00収益2025/12/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nextleaf Solutions Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Mar 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (CA$10.2m market cap, or US$7.45m). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change).
Reported Earnings • Mar 05First quarter 2026 earnings released: EPS: CA$0.002 (vs CA$0.003 in 1Q 2025)First quarter 2026 results: EPS: CA$0.002 (down from CA$0.003 in 1Q 2025). Revenue: CA$3.02m (up 4.6% from 1Q 2025). Net income: CA$259.2k (down 51% from 1Q 2025). Profit margin: 8.6% (down from 18% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 03Nextleaf Solutions Ltd., Annual General Meeting, Apr 30, 2026Nextleaf Solutions Ltd., Annual General Meeting, Apr 30, 2026.
Reported Earnings • Jan 29Full year 2025 earnings released: CA$0.001 loss per share (vs CA$0.009 loss in FY 2024)Full year 2025 results: CA$0.001 loss per share (improved from CA$0.009 loss in FY 2024). Revenue: CA$11.3m (down 9.7% from FY 2024). Net loss: CA$162.9k (loss narrowed 89% from FY 2024). Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 31Third quarter 2025 earnings released: EPS: CA$0 (vs CA$0.002 loss in 3Q 2024)Third quarter 2025 results: EPS: CA$0 (improved from CA$0.002 loss in 3Q 2024). Revenue: CA$2.91m (down 4.5% from 3Q 2024). Net loss: CA$11.9k (loss narrowed 96% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 02Second quarter 2025 earnings released: EPS: CA$0.002 (vs CA$0.006 loss in 2Q 2024)Second quarter 2025 results: EPS: CA$0.002 (up from CA$0.006 loss in 2Q 2024). Revenue: CA$3.52m (up 2.9% from 2Q 2024). Net income: CA$348.8k (up CA$1.36m from 2Q 2024). Profit margin: 9.9% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
New Risk • May 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$229k free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Market cap is less than US$10m (CA$9.17m market cap, or US$6.59m).
Reported Earnings • Mar 04First quarter 2025 earnings released: EPS: CA$0.003 (vs CA$0.001 in 1Q 2024)First quarter 2025 results: EPS: CA$0.003 (up from CA$0.001 in 1Q 2024). Revenue: CA$2.89m (down 9.9% from 1Q 2024). Net income: CA$530.4k (up 299% from 1Q 2024). Profit margin: 18% (up from 4.1% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
お知らせ • Jan 31Nextleaf Solutions Ltd. Auditor Raises 'Going Concern' DoubtNextleaf Solutions Ltd. filed its Annual on Jan 29, 2025 for the period ending Sep 30, 2024. In this report its auditor, Davidson & Company, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Reported Earnings • Jan 29Full year 2024 earnings released: CA$0.009 loss per share (vs CA$0.001 profit in FY 2023)Full year 2024 results: CA$0.009 loss per share (down from CA$0.001 profit in FY 2023). Revenue: CA$12.5m (up 53% from FY 2023). Net loss: CA$1.44m (down CA$1.66m from profit in FY 2023). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
お知らせ • Dec 26Nextleaf Solutions Ltd. Announces 14 New Product Listings Nationwide Across 4 CategoriesNextleaf Solutions Ltd. announced 14 new product listings nationally across 4 categories, and the date for their Annual General Meeting, which will be held on January 30th 2025, in Vancouver, BC. New Products and Innovation. Nextleaf announced 14 new listings under their brand Glacial Gold, across 4 categories including vapes, softgels, oils, and infused prerolls. These listings will launch between January and April 2025 nationwide. The product pipeline focuses on smokeless ingestible extracts such as softgels and oils, ready-to-consume convenience formats like All-in-One liquid diamond vapes, infused prerolls, and minor cannabinoid formulations (notably CBG and CBN) across multiple categories. These products solidify Nextleaf's market leadership in these emerging segments. Regional Product Listings. Ontario (4 new listings): Glacial Gold RSO Full Spectrum 5:5 Softgels 100-pack. Glacial Gold Atmosphere Tart Cherry CBN:THC Vape Cartridge 1.2g. Glacial Gold Atmosphere CBN:THC 15mg:15mg Oil Drops 35ml. Alberta (4 new listings: Glacial Gold Liquid Diamonds Pure Diamonds All-in-One Vape 0.95g. Glacial Gold HIGH THC Banger Cherry Bomb All-in-One Vapes 1g. Glacial Gold Atmosp Here CBN:THC 15 mg:15mg Oil Drops 35g. Glacial Gold Atmospwhere CBN:THC 15g:15mg Oil Drops 35 ml. British Columbia (6 new listings): Glacial Gold Atmosphere CBG:THC Tart Cherry Vape Cartridge 1. 2g. Glacial Gold atmospherehere CBN:THC Melon Baller Vape Cartridge1.2g. glacial Gold Atmosphere CBN;THC Oil Drops 35ml. Glacial Gold Liquid Diamonds All-in- One Vape 0.95g; Glacial Gold HIGH THC Bangers Cherry Bomb Infused Preroll 3 x 0.5g (unflavoured) Glacial Gold High THC Banger Cherry Bomb Infused Preroll3 x 0.5g.
お知らせ • Dec 02Nextleaf Solutions Ltd., Annual General Meeting, Jan 30, 2025Nextleaf Solutions Ltd., Annual General Meeting, Jan 30, 2025.
お知らせ • Sep 26Nextleaf Solutions Ltd. Appoints Emma Andrews as Permanent Chief Executive OfficerNextleaf Solutions Ltd. announced the permanent appointment of Emma Andrews as the Chief Executive Officer of the Company. Andrews has acted as the Company's Interim CEO since September 8, 2023, and has been with the company for 6 years, previously as the Director of Marketing. Emma Andrews helped guide the company's commercial strategy and led the entry into consumer-packaged goods, including the company's re-launch of prohibition-era brand Glacial Gold into the regulated landscape. Andrews brings a wealth of expertise in consumer-packaged goods, having spent over 10 years leading teams, launching brands, and developing products for the natural health industry. She is a Registered Nutritionist (RHN) and certified in New Product Development (NPDP). Her most notable tenure was with plant-based nutrition company Vega, leading to a CAD 750 million acquisition by White Wave Foods in 2015.
New Risk • Sep 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (CA$12.4m market cap, or US$9.11m). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (3.3% increase in shares outstanding).
Reported Earnings • Sep 01Third quarter 2024 earnings released: CA$0.002 loss per share (vs CA$0.003 profit in 3Q 2023)Third quarter 2024 results: CA$0.002 loss per share (down from CA$0.003 profit in 3Q 2023). Revenue: CA$3.05m (up 37% from 3Q 2023). Net loss: CA$317.3k (down 176% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
New Risk • Jun 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.7m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Reported Earnings • May 30Second quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0 in 2Q 2023)Second quarter 2024 results: CA$0.006 loss per share (further deteriorated from CA$0 in 2Q 2023). Revenue: CA$3.42m (up 57% from 2Q 2023). Net loss: CA$1.01m (loss widened CA$986.7k from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 03First quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.004 loss in 1Q 2023)First quarter 2024 results: EPS: CA$0.001 (up from CA$0.004 loss in 1Q 2023). Revenue: CA$3.20m (up 170% from 1Q 2023). Net income: CA$132.8k (up CA$691.8k from 1Q 2023). Profit margin: 4.1% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 01Full year 2023 earnings released: EPS: CA$0.001 (vs CA$0.025 loss in FY 2022)Full year 2023 results: EPS: CA$0.001 (up from CA$0.025 loss in FY 2022). Revenue: CA$8.18m (up 86% from FY 2022). Net income: CA$223.3k (up CA$3.71m from FY 2022). Profit margin: 2.7% (up from net loss in FY 2022). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
お知らせ • Oct 21Nextleaf Solutions Ltd., Annual General Meeting, Dec 19, 2023Nextleaf Solutions Ltd., Annual General Meeting, Dec 19, 2023.
お知らせ • Sep 12+ 1 more updateNextleaf Solutions Ltd. Announces an Executive ChangeThe board of directors of Nextleaf Solutions Ltd. has announced the departure of Paul Pedersen from his role as Chief Executive Officer, effective September 08, 2023. Pedersen had been Nextleaf's CEO since inception and remains on the Board of Directors. The company announced the appointment of Emma Andrews, BA, RHN, NPDP to the role of Interim Chief Executive Officer. Andrews has worked closely with Nextleaf leadership and executive team since the company's origin, most recently as the Director of Marketing she oversaw the company's entry into branded consumer products, and was integral in creating the company's mission, vision, values, and corporate identity. Andrews has held senior management and public company executive officer roles across every vertical in the cannabis industry including cultivation/harvesting, processing, retail, ancillary, and consumer products. This is in addition to over a decade working in the Natural Products Industry to help scale emerging brands into category leaders.
Reported Earnings • Sep 03Third quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.007 loss in 3Q 2022)Third quarter 2023 results: EPS: CA$0.003 (up from CA$0.007 loss in 3Q 2022). Revenue: CA$2.22m (up 85% from 3Q 2022). Net income: CA$419.9k (up CA$1.47m from 3Q 2022). Profit margin: 19% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 01Second quarter 2023 earnings released: EPS: CA$0 (vs CA$0.004 loss in 2Q 2022)Second quarter 2023 results: EPS: CA$0 (improved from CA$0.004 loss in 2Q 2022). Revenue: CA$2.17m (up 90% from 2Q 2022). Net loss: CA$25.2k (loss narrowed 96% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 03First quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0.007 loss in 1Q 2022)First quarter 2023 results: CA$0.004 loss per share (improved from CA$0.007 loss in 1Q 2022). Revenue: CA$1.19m (up 3.3% from 1Q 2022). Net loss: CA$559.0k (loss narrowed 39% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.
Reported Earnings • Jan 31Full year 2022 earnings released: CA$0.025 loss per share (vs CA$0.044 loss in FY 2021)Full year 2022 results: CA$0.025 loss per share (improved from CA$0.044 loss in FY 2021). Revenue: CA$4.41m (up 31% from FY 2021). Net loss: CA$3.49m (loss narrowed 35% from FY 2021). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Sherry Boodram was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Oct 13Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Sherry Boodram was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 16Nextleaf Solutions Ltd. Announces the Launch of New High THC Vape in Ontario and Additional Product Updates in British ColumbiaNextleaf Solutions Ltd. announced the launch of a new high THC vape in Ontario and additional product updates in British Columbia, including the Company's first cannabinol ("CBN") product. Ontario Glacial GoldTM Update - Nextleaf is excited to announce the launch of a new limited drop Glacial GoldTM vape for Ontario. The new Glacial GoldTM High THC Holiday Fruitquake is a one-gram THC vape cartridge with a holiday inspired flavour that is sweet, fruity, and cakey, reminiscent of one favourite holiday fruitcake. British Columbia Glacial GoldTM Update - Nextleaf has completed its initial shipment of its new one-gram Glacial GoldTM CBD 3:1 Vape in theCompany's signature Berry Lemonade flavour. Consumers can now find this new product in retail stores throughout B.C. Additionally, Nextleaf is delighted to announce its expansion into the rare cannabinoids market segment,specifically CBN, with the launch of Glacial GoldTM After Hours CBN:THC Drops. Formulated for night- time use, Glacial GoldTM After Hours CBN:THC Drops is the perfect blend of THC and CBN to help consumers unwind after a long day. Along with Glacial GoldTM After Hours CBN:THC Drops, there are several new Glacial GoldTM SKU listings ("SKUs") that are set to launch between now and the end of fall in British Columbia. The additional SKUs approved are Glacial GoldTM Session THC Lime Ginger Haze, Glacial GoldTM THC 10mg Softgels, and Glacial GoldTM Rise & Shine CBD Drops. Glacial GoldTM Session THC Lime Ginger Haze is a full potency one-gram THC vape cartridge. The lime ginger haze vape is cocktail inspired and consists of a citrus, lime-forward flavour, with a subtle hint of ginger. The Company has received its initial purchase order from the province and expects theproduct to be available in B.C. in early October. Glacial GoldTM THC 10mg Softgels will launch in B.C. in ten and fifty-pack formats powered by Nextleaf's high-purity cannabis distillate in a base of organic coconut MCT oil expertly encapsulated for a premium consumption experience, without premium pricing. Glacial GoldTM Softgels will provide unparalleled value in quality and price per milligram compared to other regulated capsules and edibleproducts. Glacial GoldTM Rise & Shine CBD Drops is Nextleaf's first product utilizing its technology to produce its excise-exempt ingredient, THC-free Broad Spectrum CBD distillate. The new product is a more holistic alternative to CBD isolates, perfect to start the day with no concern of THC consumption.
Reported Earnings • Aug 30Third quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.011 loss in 3Q 2021)Third quarter 2022 results: CA$0.007 loss per share (up from CA$0.011 loss in 3Q 2021). Revenue: CA$1.20m (up 83% from 3Q 2021). Net loss: CA$1.05m (loss narrowed 22% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
お知らせ • Aug 25Nextleaf Solutions Ltd. Announces the Launch of Its First THC-Free Broad Spectrum Cbd Distillate ("THC-Free CBD") ProductNextleaf Solutions Ltd. announced the launch of its first THC-free Broad Spectrum CBD distillate ("THC-Free CBD") product. Glacial GoldTM Rise & Shine CBD Drops is a broad-spectrum alternative to CBD isolates, perfect to start the day without the risk of intoxication. Nextleaf expects Glacial GoldTM Rise & Shine CBD Drops to be available first in adult-use channels in British Columbia and nationally through medical cannabis distribution partners in the fall. On July 28, 2022, Health Canada released a report by its science advisory committee on health products containing cannabis. In the report, the committee unanimously agreed that CBD is safe and tolerable for short-term use at doses from 20 milligrams per day to a max dose of 200 milligrams per day. The report will serve as a tool to inform Health Canada's decision-making in developing a potential pathway for over the counter, non-prescription health products containing CBD for humans and dogs. Nextleaf announced that it has executed its first bulk-sale of THC-Free CBD ingredients to a multinational partner. The Company recently produced THC-Free CBD in anticipation of commercialization and has validated its hemp extraction and manufacturing process through third-party analytical testing. Nextleaf believes that excise-exempt ingredients like THC-Free CBD will be disruptive ingredients within the Canadian market, and in the example of THC-Free CBD, it's an alternative to CBD isolate for those that prefer a more holistic cannabis product.
お知らせ • Jul 26Nextleaf Solutions Ltd. Announces Validation of TechnologyNextleaf Solutions Ltd. announced validation of its technology to produce THC-free Broad Spectrum CBD distillate from industrial hemp feedstock. Nextleaf is commercializing its patented technology by utilizing its new distillate-based ingredient to power the next generation of innovative CBD products distributed under the Company's prohibition-era brand, Glacial GoldTM, and supplying bulk THC-Free CBD ingredients to leading global CPG manufacturers in Canada and where cannabinoids are legal. The Company recently produced THC-Free CBD in anticipation of commercialization and has validated its hemp extraction and manufacturing process through third-party analytical testing. Nextleaf expects to announce more details in the coming weeks on the launch of its first THC-Free CBD product, and the sale of bulk cannabinoids to B2B customers that require CBD compliant for distribution in Canada and intentionally.
お知らせ • Jul 13Nextleaf Solutions Ltd. Launches Glacial Gold CBD 3:1 VapeNextleaf Solutions Ltd. announced the launch of its new CBD 3:1 vape under the award-winning prohibition-era brand, Glacial GoldTM. The Company's technology stack enables the transformation of industrial hemp biomass into CBD distillate purified to be free of wax, chlorophyll, and residual pesticides. Glacial GoldTM CBD 3:1 Vape is launching as a 1-gram format in the Company's signature Berry Lemonade flavour, reminiscent of fresh-picked berries from the Fraser Valley. The new CBD 3:1 Vape will build off the success of the Glacial GoldTM Session THC Vape and Anytime 1:1 Vape by offering an additional tier of potency at the accessible price point and quality the legacy brand is known for. The Company expects the Glacial GoldTM CBD 3:1 Vape to be available first in the British Columbia market this summer, and nationally through medical cannabis distribution partners. The British ColumbiaLiquor Distribution Branch ("BCLDB") is responsible for the wholesale distribution of cannabis to private retailers in British Columbia and is the public retailer of cannabis throughout the province under the brand 'BC Cannabis Stores'. Glacial GoldTM CBD products are manufactured using Canadian hemp flower processed at Nextleaf Labs in Greater Vancouver, B.C. Additionally, all Glacial GoldTM products are developed through the Company's extensive sensory evaluation program as covered in Forbes.
お知らせ • Jun 09Nextleaf Solutions Ltd., Annual General Meeting, Aug 03, 2022Nextleaf Solutions Ltd., Annual General Meeting, Aug 03, 2022.
Reported Earnings • Jun 01Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: CA$0.004 loss per share (up from CA$0.01 loss in 2Q 2021). Revenue: CA$1.15m (up CA$1.01m from 2Q 2021). Net loss: CA$606.9k (loss narrowed 49% from 2Q 2021). Revenue missed analyst estimates by 100%. Earnings per share (EPS) also missed analyst estimates by 43%. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings.
お知らせ • Jun 01Nextleaf Solutions Ltd. Announces Management ChangesNextleaf Solutions Ltd. announced the addition of Sam Kassem to its Board of Directors pending the issuance of his Health Canada security clearance. Mr. Kassem brings unique qualifications as a CFA charterholder with over 10 years of operational experience from servicing cannabis and hemp processors around the world. Sam Kassem is Co-Founder and President of Root Sciences Inc., one of North America's larger providers of end-to-end processing equipment solutions. Tim Gillis has resigned from the Board to pursue other interests. The Company would like to Mr. Gillis for his contribution since 2019 and wish him well on his future endeavors.
お知らせ • Apr 06Nextleaf Solutions Ltd. Announces United States Patent and Trademark Office Granted the Company its 18Th Issued U.S. PatentNextleaf Solutions Ltd. announced that the United States Patent and Trademark Office has granted the Company its 18th issued U.S. patent. Nextleaf's latest U.S. patent describes a system in which spent cannabis biomass is heated in stages to reclaim residual cannabinoids while simultaneously generating carbon with a desired porosity level. When utilized, this patented process allows Nextleaf to maximize its cannabinoid molecule yield, reduce waste destined for landfills, and create a new business vertical at minimal cost. Nextleaf owns one of the largest collections of U.S. patents among all cannabis companies, as well as a Greater Vancouver-based extraction plant producing low-cost cannabinoid ingredients under its Health Canada licences. Nextleaf's multi-patented automated extraction plant up-cycles aged cannabis flower and biomass, which would otherwise be destroyed, into high-purity cannabinoid ingredients at industrial scale.
お知らせ • Jan 12Nextleaf Solutions Ltd. Announces Glacial Gold Distilled CBD 200 Oil Available Nationally to Medical Patients Through MendoNextleaf Solutions Ltd., Glacial Gold announced that Distilled CBD 100 Oil and Distilled CBD 200 Oil are available nationally through its medical cannabis distribution partner, Quebec-based Medicibis ("Mendo").Glacial GoldTM Distilled CBD 200 Oil is a first in Canada, with the high amount of CBD in a single unit (5700 mg), high potency of CBD available in an ingestible format, and best dollar value permilligram for CBD in Canada. The Company's multi-patented ingredient processing technology is the secret behind Glacial GoldTM products. Distilled CBD 200 Oil was developed to meet the needs of the everyday CBD consumer. Glacial GoldTM CBD distilled oils are formulated with organic coconut MCT oil and a standardized doseof CBD. In British Columbia, Nextleaf is a top 10 supplier of vapes and oils. Glacial GoldTM has multiple products inside the top 20 best selling SKUs within the vape and oils categories. CBD is increasingly thought of as a potential therapeutic treatment for opioid use disorder. On January4, 2022, the FDA approved human trials evaluating an investigational drug using CBD to be conducted at UCLA and funded by the U.S. National Institute on Drug Abuse.Medical patients including veterans, have made it clear that they need a reliable supply of consistent quality medical cannabis products for those living with PTSD, chronic pain, and other conditions that disproportionately impact veterans. According to a 2019 Veterans Health and Medical CannabisStudy, 96% of veterans reported they experience a much greater quality of life because of their cannabis consumption. As part of the Company's commitment to improving access to medical cannabis, Nextleaf launched an assortment of accessibly priced Glacial GoldTM CBD and THC products for the medical market through Mendo. Quebec is the third-largest cannabis market in Canada, representing approximately 15% of Canadian cannabis retail sales in the country, and approximately 22% of the Canadian population. Canadian spending on medical cannabis totaled $587 million in 2020. Medical cannabis has become an important component of Canadian healthcare, with $119 million of medical cannabis purchases reimbursed by the Federal Government through Veterans Affairs Canada in 2020.
お知らせ • Dec 23Nextleaf Solutions Ltd. has completed a Composite Units Offering in the amount of CAD 3 million.Nextleaf Solutions Ltd. has completed a Composite Units Offering in the amount of CAD 3 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 7,500,000 Price\Range: CAD 0.2 Discount Per Security: CAD 0.016 Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 7,500,000 Price\Range: CAD 0.2 Discount Per Security: CAD 0.004 Transaction Features: Regulation S
お知らせ • Sep 24Saskatchewan Liquor and Gaming Authority Authorizes Nextleaf Solutions Ltd. to Supply Glacial GoldTM CBD and THC Products Directly to the Province's Retail and Wholesale MarketsNextleaf Solutions Ltd. announce the Saskatchewan Liquor and Gaming Authority, the provincial regulator responsible for permitting and monitoring the operation of local cannabis wholesalers and retailers in Saskatchewan, has authorized the Company to supply Glacial GoldTM CBD and THC products directly to the province's retail and wholesale markets. The model in Saskatchewan is unique as it allows for both the sale and distribution of cannabis products by the private sector. Consumers in the province can look forward to the launch of Glacial GoldTM as a price-point and value leader in distillate-focused product categories. Glacial GoldTM distillate is produced through the Company's patented, automated closed-loop, chilled-alcohol extraction plant at Nextleaf Labs, a Health Canada licensed processing facility. Nextleaf'sproprietary technology efficiently transforms cannabis and hemp grown in B.C. and throughout Canada into high-purity cannabis distillate at an industrial scale.
分析記事 • Sep 16Nextleaf Solutions (CSE:OILS) Is Carrying A Fair Bit Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Jun 25Nextleaf Solutions Ltd. Announces That the United States Patent and Trademark Office Has Granted the Company A Patent Pertaining to the Extraction and Purification of Thc and CbdNextleaf Solutions Ltd. announce that the United States Patent and Trademark Office has granted the Company a patent pertaining to the extraction and purification of THC and CBD. The Company believes it has developed defendable intellectual property around the most efficient methods for producing THC and CBD distillate at scale within a regulated market. Nextleaf owns 15 U.S. patents and has been issued over 80 patents globally.
お知らせ • Jun 16Nextleaf Solutions Ltd. to Release Adult-Use Products with THC-O-AcetateNextleaf Solutions Ltd. announce the launch of a Specialty Molecules Division to focus on the development and commercialization of novel psychoactive compounds. The division is supported by the Company's existing intellectual property ("IP") portfolio, including the manufacturing of CBD-O-acetate and the recently announced U.S. patent for the synthesis of THC-O-acetate. Nextleaf intends to develop therapeutic products from its intellectual property pertaining to the acetylation of cannabinoids. The Company expects to release adult-use products with THC-O-acetate, which to the best of the Company's knowledge has never been sold under a legal framework. The Company believes a THC-derived product produced with its patented acetylation process may hold significant potential as a therapeutic due to anecdotal reports of THC-O-acetate having a more gradual onset, longer-lasting effects, and altered psychoactive effects, as compared to Delta-9-THC. The reported enhanced potency may also have potential for reducing the cost per dose and the amount of active ingredient in a formulation to obtain the same level of effect compared to Delta-9-THC. Nextleaf's U.S. and Canadian issued patents describe a process of acetylating THC by refluxing naturally derived THC distillate in the presence of a single reactant, with THC-O-acetate the product of the reaction.
分析記事 • Jun 02Is Nextleaf Solutions (CSE:OILS) Weighed On By Its Debt Load?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Jun 02Second quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.012 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CA$130.5k (up 24% from 2Q 2020). Net loss: CA$1.19m (loss narrowed 12% from 2Q 2020).
お知らせ • May 21Nextleaf Solutions Ltd. Receives Patent to A Method for Refining Raw Cannabis Plant Material from United States Patent and Trademark OfficeNextleaf Solutions Ltd. announced that the United States Patent and Trademark Office has granted the Company a patent to a method for refining raw cannabis plant material, adding to Nextleaf's already robust and expanding U.S. patent portfolio. Nextleaf's latest U.S. patent covers a method for separating cannabinoid-rich trichomes from lower potency cannabis biomass, including most approved industrial hemp cultivars, which Nextleaf uses to increase the concentration of CBD in hemp biomass. The Company's patented technology significantly increases extraction efficiency and improves the economics of processing hemp into high-purity CBD extracts.
お知らせ • Apr 01Nextleaf Solutions Ltd. announced that it has received CAD 3 million in fundingNextleaf Solutions Ltd. (CNSX:OILS) announced that it has entered into a securities purchase agreement with an institutional investor for a private placement of a senior secured convertible note at a price of CAD 3,000,000 for gross proceeds of CAD 3,000,000 on March 31, 2021. The company will also issue a warrant to purchase up to 6,875,000 common shares. The was issued at an original issue discount of 10% and were of the principal amount of CAD 3,300,000. The note will mature on the date that is 18 months from the date of issuance and bear guaranteed interest at a rate of 5% per annum. The warrant is exercisable into common shares at a price of CAD 0.288 per share for a period of 36 months from the date of issuance. The company issued 250,000 common hares at a deemed price of CAD 0.24 per share as fees related to the transaction. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date.
お知らせ • Mar 19Nextleaf Solutions Ltd., Annual General Meeting, May 14, 2021Nextleaf Solutions Ltd., Annual General Meeting, May 14, 2021.
お知らせ • Mar 11BevCanna Enterprises Inc. Signs Supply Agreement with Nextleaf Solutions LtdBevCanna Enterprises Inc. has signed a supply agreement with Nextleaf Solutions Ltd. BevCanna will have the ability to utilize Nextleaf's Rapid Emulsion Technology by OILSTM (‘Rapid’) THC and CBD concentrate within select BevCanna in-house and white-label products. Made with Nextleaf's high purity cannabis distillate, Rapid's unique structure and composition allows the final ingredient to be fundamentally tasteless, odorless, and achieve optical transparency through uniform and complete dispersion in water. Ten years of prior R&D has resulted in a patent pending emulsion technology adapted to cannabinoids, to deliver rapid onset of THC, CBD, and other cannabinoids. The recent receipt of BevCanna's Health Canada Standard Processing License has allowed the Company to move forward with commercial validation and go-to-market activities, and the Company is actively working with its partners, including Nextleaf, on these initiatives.
お知らせ • Mar 06Nextleaf Solutions Supplies Rapid Emulsion to Cannabis-Infused Beverage Manufacturer BevcannaNextleaf Solutions Ltd. announced the initial order of Nextleaf's Rapid Emulsion Technology by OILSTM ("Rapid") THC and CBD to cannabis-infused beverage manufacturer, BevCanna Enterprises Inc. ("BevCanna"). With this initial order, Nextleaf's Rapid concentrate becomes one of BevCanna's preferred ingredients, available for use in both their brands and their partner brands. Rapid is Nextleaf's patent pending delivery technology.
Reported Earnings • Mar 04First quarter 2021 earnings released: CA$0.008 loss per share (vs CA$0.012 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CA$1.26m (up 259% from 1Q 2020). Net loss: CA$911.5k (loss narrowed 31% from 1Q 2020).
お知らせ • Feb 18Nextleaf Solutions Ltd. Receives Cannabis Extraction Patent in IsraelNextleaf Solutions Ltd. announced the Israeli Patent Office has granted the Company a patent for its foundational process for producing low-cost cannabis distillate, Nextleaf's fifth issued extraction patent in Israel. The Company believes global patent protection is a key aspect of developing defendable intellectual property ("IP") around the most efficient methods for producing high-purity THC and CBD oils within a regulated environment. With the medical cannabis market in Israel continuing to grow along with the tailwind of legalization, Nextleaf views Israel as a key jurisdiction for cannabinoid IP rights. In December 2020, Israel signed a regulatory amendment permitting the use of CBD in cosmetics and food products. According to the Israeli Medical Cannabis Association, there are over 71,000 legal medical cannabis patients, in addition to an estimated $2 Billion in illicit cannabis consumption in Israel. Nextleaf owns one of the large portfolios of issued U.S. patents related to cannabis extraction, and has been issued patents in Canada, Mexico, Australia, New Zealand, Colombia, South Africa, Cambodia, Israel, Germany, the U.K. and across Europe.
お知らせ • Jan 20Nextleaf Solutions Grants Patent for CBD Prodrug and Prepares for Pharmaceutical ParticipationNextleaf Solutions Ltd. announced that the Canadian Intellectual Property Office has granted the company a patent for the acetylation of cannabinoids. More specifically, the patent covers a process for acetylating cannabidiol ("CBD"), and subsequent refinement of CBD-O-Acetate using a proprietary extraction and distillation technique. The company owns 12 issued U.S. patents and 70 issued patents globally for the extraction, purification, and delivery of cannabinoids - representing the patent portfolio among all cannabis companies. This patented process to produce CBD-O-Acetate enables the standardization of a more potent analog of CBD through targeted drug delivery. Prodrugs utilize various physical and chemical modifications to improve features of active drugs. Maintaining the integrity of the molecule and its ability to deliver drugs to precisely targeted areas in the body may increase efficacy for desired outcomes. The company believes an orally consumable CBD metabolic prodrug produced under its patented process for acetylating cannabidiol will enhance the therapeutic potency of CBD. OILS already owns U.S. patents for the acetylation of THC, and the acetylation of CBD. The company's patent portfolio and Health Canada licenses for cannabis processing and research presents an entry point for pharmaceutical firms looking to manufacture cannabinoid prodrugs in a federally legal jurisdiction. The company plans to commercialize this intellectual property ("IP") through IP licensing, and the production of IP protected cannabinoid-based products as legally permitted by Health Canada. Nextleaf has engaged Kronos Capital Partners Inc. ("Kronos") to pursue and evaluate global strategic partners and investors. Kronos is a strategic advisor and an active investor in the global cannabis and life science sectors.
お知らせ • Jan 12Nextleaf Solutions Ltd. Wins U.S. Patent for Cannabis Extract and Launches CBD OilsNextleaf Solutions Ltd. announced that the United States Patent and Trademark Office has granted the Company a patent for a process resulting in a solventless cannabis concentrate, adding to the Company's dynamic and expanding U.S. patent portfolio. The Company owns 12 issued U.S. patents and over 60 issued patents globally for the extraction, purification, and delivery of cannabinoids. Nextleaf's latest U.S. patent covers a process whereby trichomes are made brittle from exposure to low temperatures and separated from plant material during agitation and through a series of filtration. The result is a proprietary full melt bubble hash concentrate, a product category that makes up approximately 10% of the cannabis market in the United States. This patent further enriches the Company's intellectual property around differentiated formats and delivery technology. OILS commercializes its intellectual property in Canada through its wholly-owned subsidiary, Nextleaf Labs Ltd. Nextleaf Labs delivered approximately 100 kilos of CBD distillate to one of Canada's top selling cannabis brands during the month of December. Nextleaf Labs' bulk cannabis distillate supply agreement is with a British Columbia-based licensed producer and one of the largest distributors of cannabis products in Canada. Nextleaf expects to continue supplying CBD distillate to the Partner for the purposes of manufacturing CBD based products, with distribution of the Partner's branded consumer products through their existing sales channels.
Is New 90 Day High Low • Jan 07New 90-day high: CA$0.21The company is up 16% from its price of CA$0.18 on 09 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 60% over the same period.
お知らせ • Nov 27Nextleaf Solutions Granted Mexican Patent and Signs Cannabis Extraction AgreementNextleaf Solutions Ltd. to provide the following commercial and intellectual property update: Cannabis Extraction Agreement with White Label Producer: The Company's wholly owned subsidiary Nextleaf Labs Ltd. has entered into a Cannabis Extraction Agreement with a licensed producer in Ontario, which is a premium white label flower producer. Pursuant to the Extraction Agreement, the Client provides cannabis biomass to be processed into THC distillate by Nextleaf Labs. The extraction services may be paid in-kind, with Nextleaf Labs retaining a portion of the resulting bulk THC distillate. The initial term of the Agreement will end on the earlier of (a) 12 months, and (b) the date upon which 1,000 kilos of marijuana have been processed by Nextleaf Labs. Nextleaf Labs wholesales THC and CBD oils through its Commercial Partners Program and provides cannabis extraction services. The Company's investment in intellectual property and its automated closed-loop extraction plant provides a clear competitive advantage supplying low-cost cannabinoid distillate. The Mexican Institute of Industrial Property has granted OILS a patent for the Company's foundational process for producing high-purity cannabinoid distillate. On September 19, 2020 the Mexican Senate approved a comprehensive adult-use marijuana legalization bill. The pending law requires President Andrés Manuel López Obrador signing the bill into law, which will make Mexico the third country to legalize adult-use cannabis, following Canada and Uruguay. Once signed, Mexico will become the legal cannabis market in the world, based on population. Nextleaf owns the second patent portfolio of any cannabis company, and has been issued patents in Canada, the United States, Israel, Australia, New Zealand, Mexico, Colombia, South Africa, the U.K. and across Europe.